Matteo Borsani

University of Turin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Laura Cavallarin

National Research Council

Marzia Giribaldi

Institute of Sciences of Food Production

Monica Asteggiano

Ospedale Maria Vittoria

Elena Spada

Vita-Salute San Raffaele University

Federica Chiale

Ospedale Maria Vittoria

Guido E. Moro

Mothers’ Milk Bank

Alessandra Coscia

University of Turin

Sonia Deantoni

University of Turin

Chiara Peila

University of Turin

Ivan Cortinovis

University of Milan

Cooperative Institutions

University of Turin

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

University of Milan

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

National Research Council

Institute of Sciences of Food Production

National Academies of Sciences, Engineering, and Medicine

Environment Park

Ospedale Maria Vittoria

Istituti di Ricovero e Cura a Carattere Scientifico

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The Use of a Novel Donkey Milk-Derived Human Milk Fortified in the Neonatal Period Had No Effect on the Frequency of Allergic Manifestations During the First Years of Life: The “Fortilat Trial” Follow-Up

Breastfeeding Medicine (2024)

Chiara Peila Elena Spada Sonia Deantoni Matteo Borsani Monica Asteggiano

Background: Since human milk contents does not meet the high need of very low birth weight infants, fortification of breast milk is a standard practice for this population. As donkey milk has been long considered for children allergic to cow's milk proteins due to its low allergic properties, a new donkey milk-derived fortifier (DF) has been recently evaluated as a valid alternative to bovine milk-derived fortifier (BF). It seems to improve feeding tolerance when compared with standard BF, with similar neurodevelopmental and auxological outcome at 18 months of age. The aim of this study is to evaluate the development of allergic manifestations occurring in the population of the "Fortilat Trial" at 6–8 years of age. Methods: Allergic manifestations were assessed by an ad hoc questionnaire administered to families. The occurrence of asthma, allergic rhinitis and oculorhinitis, rashes and atopic dermatitis, food allergies, accesses to an emergency department for allergic reactions, and the need of antihistamine have been investigated. Results: In total, 113 infants were enrolled in the study (BF arm: n = 60, DF arm: n = 53). No difference in risk was observed between the two groups for all the considered outcomes. In conclusion, our data suggest that DF does not impact the development of allergic manifestations in the first years of life. Clinical Trial Registration number: ISRCT N70022881

Milk allergy

10.1089/bfm.2023.0320

Cite

Citations (1)